



## Supplementary Information

# Synergistic in vitro Antiviral Effect of Combinations of Ivermectin, Essential Oils and 18-(Phthalimid-2-yl)ferruginol Against Arboviruses and Herpesvirus

Liliana Betancur-Galvis <sup>1,\*</sup>, Orlando José Jimenez-Jarava <sup>1</sup>, Fatima Rivas <sup>2</sup>, William E. Mendoza-Hernández <sup>3</sup>, and Miguel A. González-Cardenete <sup>3,\*</sup>

<sup>1</sup> Grupo GRID- Grupo de Investigaciones Dermatológicas, Instituto de Investigaciones Médicas, Facultad de Medicina, Universidad de Antioquia, 050010 Medellín, Colombia


<sup>2</sup> Department of Chemistry, Louisiana State University, 133 Chopping Hall, Baton Rouge, Louisiana 70803, United States.

<sup>3</sup> Instituto de Tecnología Química, Universitat Politècnica de València-Consejo Superior de Investigaciones Científicas, Avda. de los Naranjos s/n, 46022 Valencia, Spain.


Email: migoncar@itq.upv.es

## Contents

- Swissadme analysis for compound **1a** .....Figure S1, page S2
- Swissadme analysis for compound **2** .....Figure S2, page S3
- Table S1: In vitro pharmacokinetic data **1a**: Caco2 permeability .....Table S1, page S4
- Table S2: In vitro pharmacokinetic data **1a**: stability in microsomes and plasma.....Table S2, page S4



SMILES: CC(c1cc2CC[C@@H]3[C@](c2cc1O)(C)CCC[C@@]3(C)CN1C(=O)c2c(C1=O)cccc2)C



SMILES: OC(=O)[C@]1(C)CCC[C@]2([C@H]1CCc1c2cc(c(c1)C(C)C)S(=O)(=O)[O-])C.[Na+]

**Table S1.** In vitro pharmacokinetic parameters for compound phthFGL (**1a**): Caco2 permeability.<sup>a</sup>

Compound ID	Caco2 Permeability				
	AVG Papp A/B (nm/s)	SD Papp A/B	AVG Papp B/A (nm/s)	SD Papp B/A	Efflux Ratio (B2A/A2B)
Cambamazepine	718.9	12.5	565.9	32.8	0.8
Digoxin	46.1	4.6	270.6	20.5	5.9
<b>1a</b>	227.8	49.9	92.7	28.8	0.4

<sup>a</sup> See experimental methods in reference: Ling, T.; Tran, M.; González, M.A.; Gautam, L.N.; Connelly, M.; Wood, R.K.; Fatima, I.; Miranda-Carboni, G.; Rivas, F. (+)-Dehydroabietylamine derivatives target triple-negative breast cancer. *Eur. J. Med. Chem.* **2015**, *102*, 9–13. <https://doi.org/10.1016/j.ejmech.2015.07.034>

**Table S2.** In vitro pharmacokinetic parameters for compound phthFGL (**1a**): stability in microsomes and plasma.<sup>a</sup>

Compound ID	Metabolic Stability (Human)			Metabolic Stability (Mouse)				Plasma Stability (Human)		Plasma Stability (Mouse)	
	t1/2 (hr)	STD	Clint (mL/Min/Kg)	t1/2 (hr)	STD	Clint (mL/Min/Kg)		t1/2 (hr)	STD	t1/2 (hr)	STD
Verapamil	2.10	0.2	9.9	1.32	0.1	43.4	Eucatropine	0.57	0.01	4.96	0.28
<b>1a</b>	3.53	1.1	5.9	3.83	0.8	14.9	<b>1a</b>	52.58	6.11	>>48	--

<sup>a</sup> See experimental methods in reference: Ling, T.; Tran, M.; González, M.A.; Gautam, L.N.; Connelly, M.; Wood, R.K.; Fatima, I.; Miranda-Carboni, G.; Rivas, F. (+)-Dehydroabietylamine derivatives target triple-negative breast cancer. *Eur. J. Med. Chem.* **2015**, *102*, 9–13. <https://doi.org/10.1016/j.ejmech.2015.07.034>